Short Interest in Innate Pharma S.A. (NASDAQ:IPHA) Expands By 5.7%

Innate Pharma S.A. (NASDAQ:IPHA) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 81,300 shares, a growth of 5.7% from the March 31st total of 76,900 shares. Based on an average daily trading volume, of 10,400 shares, the days-to-cover ratio is presently 7.8 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $11.50 price objective on shares of Innate Pharma in a report on Thursday, April 11th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Innate Pharma stock. Exchange Traded Concepts LLC increased its stake in shares of Innate Pharma S.A. (NASDAQ:IPHA) by 34.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,888 shares of the company’s stock after purchasing an additional 11,890 shares during the quarter. Exchange Traded Concepts LLC owned 0.06% of Innate Pharma worth $131,000 at the end of the most recent quarter. Institutional investors own 0.16% of the company’s stock.

Innate Pharma Price Performance

IPHA opened at $2.54 on Thursday. Innate Pharma has a 12 month low of $1.81 and a 12 month high of $3.57. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.73 and a quick ratio of 3.73. The business has a fifty day moving average price of $2.53 and a 200 day moving average price of $2.55.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.